Allergic Rhinitis Due to Dust Mite

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Stallergenes Greer
Stallergenes GreerFrance - Antony
1 program
1
300 IR house dust mites allergen extract tabletPhase 31 trial
Active Trials
NCT01199133Terminated471Est. Sep 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stallergenes Greer300 IR house dust mites allergen extract tablet

Clinical Trials (1)

Total enrollment: 471 patients across 1 trials

NCT01199133Stallergenes Greer300 IR house dust mites allergen extract tablet

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Start: Oct 2009Est. completion: Sep 2011471 patients
Phase 3Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space